In 2003, Orient EuroPharma Co., Ltd. (OEP) acquired the subsidiary company of ElanPharma, an Irish company, established Orient EuroPharma Philippines Inc (OEP PH). After years of hard work, OEP PH was ranked 35th place by sales in the list of Western pharmaceutical companies in 2017 Q2. OEP PH markets prescription medicine includes: cardiovascular drugs for hypertension; oncology drugs; respiratory drugs for asthma and chronic obstructive pulmonary disease; metabolic drugs and antibiotics for infections.
To provide more variety of high-quality products, we continued to seek out partnership. In 2012, a professional dermo-cosmetics team was organized to open up the market in Philippines.
OEP PH continued to develop at a stable pace and recruit more professional experts. Meanwhile, by sharpening the sale techniques, the company cultivated a group of professionals in the Asian Pacific region.
Orient EuroPharma Singapore (OEP SG) was established in 1993, with an emphasis on products for prescription drugs and nutritional market. The company showed advantages in oncology, urology, neuroscience, and basic medicine. OEP SG markets products including Navelbine (in injection and capsule form) for non-small cell lung cancer and breast carcinoma; anti-parkinson's disease drug; non-invasive Androgel for testosterone deficiency; Permixon for benign prostatic hypertrophy; and Pamorelin® for prostatic cancer.
In 2018, the Wealth Magazine in Taiwan announced the Top 100 Taiwanese Business in ASEAN. The subsidiary in Singapore was ranked 88th in the 2015 and 2016 Top 100 Taiwanese Business in ASEAN for revenue and profit growth, and its business results have been recognized by external communities.
Orient EuroPharma Malaysia (OEP MY) was established in 1997. Major products include: Navelbine (an injection and oral dose form) for breast and lung cancer; and Zanidip, a new generation of lipophilic calcium blocker, for chronic hypertension (benefit of avoiding edema side effect); hypertensive drugs; diabetic drug; anti-parkinson's disease drug and non-invasive Androgel for testosterone deficiency. In 2012, Foster for asthma and Vimpat for seizures were marketed. With so many different innovative drugs, OEP MY would certainly become one of the dominant pharmaceutical companies in Malaysia.
Karihome products were launched in Malaysia in 2005, consistently leading goat milk powder products in the area. The team of Karihome products has also continuously established positive word of mouth through various activities, all in an effort to promote Karihome products for more families to enjoy.
Dermo-cosmetics team was established in 2016, selling Germany’s Hyabell injectable hyaluronic acid products to expand the medical cosmetic markets in Malaysia.
The Vietnam Office was established in 2011, and a subsidiary was officially inaugurated in 2017, entering the Vietnamese market with OEP’s new anti-hyperlipidemia drug. OEP will introduce other drugs and nutritional supplements in the future.
Orient EuroPharma Co., Ltd. (OEP) officially entered the China market in 2006, starting with establishments in Shanghai and Guangzhou. In 2008, the Karihome goat series milk powder was officially introduced in the market. By partnership with local retailers, the Karihome goat Series milk powder was successfully introduced to North China and expended to East, West and South China.
A complete marketing network for OEP was established in China in 2014, with scope of marketing covering all provinces, cities, and districts across the country. In the same year, AC Nelsen survey report indicates that Karihome has become the leading goat milk brand for Chinese consumers. In November 2017, Karihome products received the Product Formula Registration Certificate for Infant Formula Milk Powder by the China Food and Drug Administration. This achievement highlights the Administration’s recognition of Karihome products and OEP's comprehensive capabilities in biotechnology.